drugset / Trial / NCT01275274
Retinoids in ANCA Small Vessel Vasculitis: Silencing Autoantigens
Phase 2
Withdrawn
University of North Carolina, Chapel Hill
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this research study is to learn if adding all-trans retinoic acid (tretinoin) to conventional treatment of Anti- Neutrophil Cytoplasmic Autoantibodies (ANCA) vasculitis can decrease the level of disease activity.
Timeline
- Start
- 2012-01
- Primary completion
- 2013-12
- Completion
- 2013-12
Outcome
Outcome not reported
Stopped (Enrollment): “no subject enrolled in nearly 2 years”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tretinoin | Unknown | 22.5 mg/m2 | Oral |
| Subject | Tretinoin | Unknown | 45 mg/m2 | Oral |
| Comparator | Azathioprine | Small molecule | — | — |
| Comparator | Mycophenolate Mofetil | Small molecule | — | — |
| Comparator | Prednisone | Other / unclassified | — | — |